CRANBURY, N.J. , March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) for ONS-5010.

CRANBURY, N.J. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal quarter ended December 31, 2018 . Recent Highlights: Reached 75% enrollment completion in ONS-5010-001, a Phase 3

CRANBURY, N.J. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business

CRANBURY, N.J. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK, OTLKW) (the “Company”) today announced that its publicly traded Series A warrants (Nasdaq: OTLKW) have been amended to lower the exercise price to $1.50 per share and further extend the maturity until 5:00

CRANBURY, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business

CRANBURY, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK ) (the “Company”) today reported financial results and business highlights for its fiscal year ended September 30, 2018. Recent Highlights: Initiated ONS-5010 clinical study in wet AMD with first patient

Company changes name to Outlook Therapeutics, Inc. ; ticker symbol to “OTLK” Jeff Evanson joins team as Chief Commercial Officer Terry Dagnon joins team as Chief Operating Officer Closed second tranche of private placement for additional $4.0 million from BioLexis CRANBURY, N.J. , Dec.

Receives commitment for $20 million in proceeds from equity private placement Restructures and extends maturity on $13.5 million of outstanding senior secured notes CRANBURY, N.J. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it has begun dosing patients

CRANBURY, N.J. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ: ONS) today reported financial results and business highlights for its three and nine months ended June 30, 2018 . Recent Highlights: Continued to prepare ONS-5010 for clinical trials Converted majority of Series A

CRANBURY, N.J. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that Lawrence A. Kenyon , its Chief Financial Officer (CFO) and Corporate Secretary, has been appointed to the role of President and Chief Executive Officer (CEO), and has joined the Company’s Board